Abbott Abbokinase
Reovirus was found in three lots of in-process urokinase product, FDA reports in a March 16 letter. The reovirus was detected because of testing begun this year by Abbott after FDA found production deficiencies in an inspection last fall ("The Pink Sheet" Feb. 15, p. 9). Finished lots of Abbokinase currently on the market have tested negative for reovirus in Abbott's preliminary test, but FDA noted that the test has not been validated. Additional finished lots of Abbokinase will not be available until further testing and testing validation has been completed
More from Archive
Advanz Pharma would have had to show that the European Commission’s decision to revoke Ocaliva’s conditional marketing approval risked causing serious and irreparable harm, according to lawyers from Van Bael & Bellis.
This is your final call to participate in the survey to better understand our subscribers’ content and delivery needs. The deadline is 20 September.
We are conducting a survey to better understand our subscribers’ content and delivery needs. If there are any changes you’d like to see in coverage topics, article format, or the method in which you access the Pink Sheet – or if you love it how it is – now is the time to have your voice heard.
A new pilot aims to take Brazil closer to ‘digital transformation.’